A Phase 1 interventional study of azacitidine in MDS, AML and Solid Tumors, sponsored by Celgene. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-19.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing azacitidine in Multiple Myeloma — none open to participants now, 1 under way, none of them phase 3. Azacitidine · Multiple Myeloma.
Among the 10 studies testing azacitidine in Multiple Myeloma, this one is one of 2 that started in 2008, is one of 4 in phase 1, and was the 3rd registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →None of the 10 studies testing azacitidine in Multiple Myeloma is open now. The open studies under Multiple Myeloma, anywhere →
Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5
First in 2000; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 21 across the 9 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 7 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
149 studies in Multiple Myeloma by Bristol-Myers Squibb: 9 open now, 18 under way, 6 of them phase 3. Of 120 finished, 43 (36%) have results posted.
Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 81st largest by enrollment of the 108 interventional ones that give a count, is one of 10 that started in 2008, is one of 40 in phase 1, and was the 21st registered.
Bristol-Myers Squibb’s Multiple Myeloma studies by the year they started, since 2001.
1 of the studies testing azacitidine in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04174196Memorial Sloan Kettering Cancer CenterA Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma | 2026-11-19 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing azacitidine in Multiple Myeloma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 149 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate three things. The first being whether azacitidine is absorbed in the body at the same rate or proportion for different concentrations. The second is to determine the effect renal impairment has or does not have on the absorption of azacitidine. The third is to determine if azacitidine is safe and well tolerated in patients with renal function impairment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of one of the following:
Have average calculated of:
Have organ and marrow function at the screening and pre-dose visits as defined below:
Have serum bicarbonate:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with normal renal function received a single subcutaneous dose of azacitidine 25 mg/m\^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m\^2 daily on Days 1-7 of each 28-day cycle.
Drug: azacitidine
Participants with normal renal function received a single subcutaneous dose of azacitidine 50 mg/m\^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m\^2 daily on Days 1-7 of each 28-day cycle.
Drug: azacitidine
Participants with normal renal function received subcutaneous doses of azacitidine 75 mg/m\^2 on Days 1 to 5. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m\^2 daily on Days 1-7 of each 28-day cycle.
Drug: azacitidine
Participants with normal renal function received a single subcutaneous dose of azacitidine 100 mg/m\^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m\^2 daily on Days 1-7 of each 28-day cycle.
Drug: azacitidine
Participants with severe renal impairment (RI; defined as creatinine clearance \< 30 mL/min/1.73 m\^2) received subcutaneous doses of azacitidine 75 mg/m\^2 on Days 1 to 5. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m\^2 daily on Days 1-7 of each 28-day cycle.
Drug: azacitidine
Also known as: Vidaza
Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) of azacitidine following a single dose of azacitidine on Day 1, calculated by the linear trapezoidal rule.
Time frame: Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point
Area under the plasma concentration-time curve from time zero to the last quantifiable time point (AUC0-t) of azacitidine following a single dose of azacitidine on Day 1, calculated by the linear trapezoidal rule.
Time frame: Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity
The area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) for azacitidine after a single dose, calculated by the linear trapezoidal rule and extrapolated to infinity according to the following equation: AUC0-inf = AUC0-t + (Ct/ke), where Ct is the last quantifiable concentration and ke = elimination rate constant.
Time frame: Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Maximum Plasma Concentration of Azacitidine (Cmax)
The maximum observed plasma concentration of azacitidine after a single dose on Day 1.
Time frame: Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Time to Maximum Plasma Concentration of Azacitidine (Tmax)
The time to first maximum observed plasma concentration of azacitidine after a single dose on Day 1.
Time frame: Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Terminal Phase Half-life of Azacitidine (t½)
The terminal phase half-life of azacitidine after a single dose on Day 1, calculated according to the following equation: t½ = 0.693/λz, where λz is the terminal phase rate constant.
Time frame: Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Apparent Total Clearance of Azacitidine (CL/F)
The apparent total clearance of azacitidine after a single dose on Day 1, calculated as Dose/AUC0-inf.
Time frame: Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Apparent Volume of Distribution of Azacitidine (Vz/F)
The apparent volume of distribution of azacitidine after a single dose on Day 1, calculated according to the equation: Vz/F = Apparent total clearance (CL/F) / terminal phase rate constant (λz)
Time frame: Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose After Single and Multiple Doses of Azacitidine
The effect of renal impairment on azacitidine pharmacokinetics was analyzed by comparing PK parameters obtained on Days 1 and 5 from participants with severe renal impairment and those with normal renal function. Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) of azacitidine following a single dose (Day 1) and multiple doses (Day 5) was calculated by the linear trapezoidal rule.
Time frame: Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Time Point After Single and Multiple Doses of Azacitidine
The area under the plasma concentration-time curve from time zero to the last quantifiable time point (AUC0-t) of azacitidine following a single dose (Day 1) and multiple doses (Day 5) was calculated by the linear trapezoidal rule for participants with normal renal function and for participants with severe renal impairment.
Time frame: Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity After Single and Multiple Doses of Azacitidine
The area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) for azacitidine, after a single dose (Day 1) and multiple doses (Day 5), calculated by the linear trapezoidal rule and extrapolated to infinity according to the following equation: AUC0-inf = AUC0-t + (Ct/ke), where Ct is the last quantifiable concentration and ke = elimination rate constant.
Time frame: Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Maximum Plasma Concentration of Azacitidine (Cmax) After Single and Multiple Doses of Azacitidine
The maximum observed plasma concentration of azacitidine after a single dose (Day 1) or multiple doses (Day 5) for participants with normal renal function and for participants with severe renal impairment.
Time frame: Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Time to Maximum Plasma Concentration of Azacitidine (Tmax) After Single and Multiple Doses of Azacitidine
The time to first maximum observed plasma concentration of azacitidine after a single dose (Day 1) or multiple doses (Day 5) for participants with normal renal function and severe renal impairment.
Time frame: Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Terminal Phase Half-life of Azacitidine (t½) After Single and Multiple Doses of Azacitidine
The terminal phase half-life of azacitidine after a single dose (Day 1) or multiple doses (Day 5) for participants with normal renal function and severe renal impairment, calculated according to the following equation: t½ = 0.693/λz, where λz is the terminal phase rate constant.
Time frame: Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Apparent Total Clearance of Azacitidine (CL/F) After Single and Multiple Doses of Azacitidine
The apparent total clearance of azacitidine after a single dose (Day 1) and multiple doses (Day 5) for participants with normal renal function and severe renal impairment, calculated as Dose/AUC0-inf.
Time frame: Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Apparent Volume of Distribution of Azacitidine (Vz/F) After Single and Multiple Doses of Azacitidine
The apparent volume of distribution of azacitidine after a single dose (Day 1) and multiple doses (Day 5) for participants with normal renal function and severe renal impairment, calculated according to the equation: Vz/F = Apparent total clearance (CL/F) / terminal phase rate constant (λz).
Time frame: Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Number of Participants With Adverse Events (AEs)
A serious adverse event is one that at any dose of the study drug or at any time during the period of observation: * Results in death; * Is life threatening; * Requires inpatient hospitalization or prolongation of existing hospitalization; * Results in persistent or significant disability/incapacity; * Is a congenital anomaly/birth defect; * Is medically important. The Investigator assessed each AE for potential causal relationship between the event and study drug. The intensity of adverse changes in physical signs or symptoms was graded from 1 to 5 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3, and according to the following: Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3), Life threatening (Grade 4), or Death (Grade 5).
Time frame: Initial treatment phase: Days 1-11 for participants who received a single dose; Days 1-29 for participants who received multiple doses. Extension treatment period: From the date of first dose until 28 days after the date of last dose (up to 7 months).
| Milestone | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 | Extension Phase: Normal RF | Extension Phase: Severe RI |
|---|---|---|---|---|---|---|---|
| Started | 5 | 5 | 7 | 6 | 8 | 0 | 0 |
| Received study drug | 5 | 5 | 6 | 5 | 6 | 0 | 0 |
| Completed | 5 | 5 | 6 | 5 | 5 | 0 | 0 |
| Not completed | 0 | 0 | 1 | 1 | 3 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Sponsor request | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 | Extension Phase: Normal RF | Extension Phase: Severe RI |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 14 | 4 |
| Completed | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 12 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| Withdrew: No longer receiving clinical benefit | 0 | 0 | 0 | 0 | 0 | 6 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) of azacitidine following a single dose of azacitidine on Day 1, calculated by the linear trapezoidal rule.
| ng*hr/mL | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 |
|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose | 455.86 ± 26.04 | 897.43 ± 31.00 | 921.87 ± 39.215 | 1502.86 ± 25.57 |
Area under the plasma concentration-time curve from time zero to the last quantifiable time point (AUC0-t) of azacitidine following a single dose of azacitidine on Day 1, calculated by the linear trapezoidal rule.
| ng*hr/mL | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 |
|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point | 454.80 ± 26.22 | 895.38 ± 31.20 | 920.76 ± 39.20 | 1505.16 ± 25.57 |
The area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) for azacitidine after a single dose, calculated by the linear trapezoidal rule and extrapolated to infinity according to the following equation: AUC0-inf = AUC0-t + (Ct/ke), where Ct is the last quantifiable concentration and ke = elimination rate constant.
| ng*hr/mL | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 |
|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity | 460.47 ± 25.79 | 897.42 ± 30.93 | 945.50 ± 39.05 | 1533.37 ± 23.96 |
The maximum observed plasma concentration of azacitidine after a single dose on Day 1.
| ng/mL | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 |
|---|---|---|---|---|
| Maximum Plasma Concentration of Azacitidine (Cmax) | 293.38 ± 34.11 | 749.04 ± 61.03 | 745.50 ± 57.90 | 1261.96 ± 39.19 |
The time to first maximum observed plasma concentration of azacitidine after a single dose on Day 1.
| hours | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 |
|---|---|---|---|---|
| Time to Maximum Plasma Concentration of Azacitidine (Tmax) | 0.25 (0.25 to 1.00) | 0.25 (0.25 to 0.78) | 0.25 (0.25 to 0.50) | 0.27 (0.25 to 0.75) |
The terminal phase half-life of azacitidine after a single dose on Day 1, calculated according to the following equation: t½ = 0.693/λz, where λz is the terminal phase rate constant.
| hours | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 |
|---|---|---|---|---|
| Terminal Phase Half-life of Azacitidine (t½) | 1.38 ± 27.31 | 0.63 ± 35.72 | 1.19 ± 102.56 | 1.03 ± 78.48 |
The apparent total clearance of azacitidine after a single dose on Day 1, calculated as Dose/AUC0-inf.
| liters/hour | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 |
|---|---|---|---|---|
| Apparent Total Clearance of Azacitidine (CL/F) | 104.58 ± 25.00 | 105.76 ± 17.03 | 151.55 ± 30.88 | 106.00 ± 25.64 |
The apparent volume of distribution of azacitidine after a single dose on Day 1, calculated according to the equation: Vz/F = Apparent total clearance (CL/F) / terminal phase rate constant (λz)
| liters | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 |
|---|---|---|---|---|
| Apparent Volume of Distribution of Azacitidine (Vz/F) | 208.69 ± 45.57 | 96.74 ± 36.75 | 259.44 ± 121.71 | 456.69 ± 99.41 |
The effect of renal impairment on azacitidine pharmacokinetics was analyzed by comparing PK parameters obtained on Days 1 and 5 from participants with severe renal impairment and those with normal renal function. Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) of azacitidine following a single dose (Day 1) and multiple doses (Day 5) was calculated by the linear trapezoidal rule.
| ng*hr/mL | Normal RF: Azacitidine 75 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 |
|---|---|---|
| Day 1 | 921.87 ± 39.15 | 1558.32 ± 64.95 |
| Day 5 | 843.03 ± 12.00 | 1183.61 ± 51.92 |
The area under the plasma concentration-time curve from time zero to the last quantifiable time point (AUC0-t) of azacitidine following a single dose (Day 1) and multiple doses (Day 5) was calculated by the linear trapezoidal rule for participants with normal renal function and for participants with severe renal impairment.
| ng*hr/mL | Normal RF: Azacitidine 75 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 |
|---|---|---|
| Day 1 | 920.76 ± 39.20 | 1558.72 ± 65.02 |
| Day 5 | 841.62 ± 11.83 | 1181.83 ± 51.98 |
The area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) for azacitidine, after a single dose (Day 1) and multiple doses (Day 5), calculated by the linear trapezoidal rule and extrapolated to infinity according to the following equation: AUC0-inf = AUC0-t + (Ct/ke), where Ct is the last quantifiable concentration and ke = elimination rate constant.
| ng*hr/mL | Normal RF: Azacitidine 75 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 |
|---|---|---|
| Day 1 | 946.22 ± 39.05 | 1573.82 ± 63.46 |
| Day 5 | 857.64 ± 9.94 | 1210.92 ± 49.07 |
The maximum observed plasma concentration of azacitidine after a single dose (Day 1) or multiple doses (Day 5) for participants with normal renal function and for participants with severe renal impairment.
| ng/mL | Normal RF: Azacitidine 75 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 |
|---|---|---|
| Day 1 | 745.50 ± 57.90 | 1056.66 ± 93.01 |
| Day 5 | 632.56 ± 45.86 | 668.11 ± 91.64 |
The time to first maximum observed plasma concentration of azacitidine after a single dose (Day 1) or multiple doses (Day 5) for participants with normal renal function and severe renal impairment.
| hours | Normal RF: Azacitidine 75 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 |
|---|---|---|
| Day 1 | 0.25 (0.25 to 0.50) | 0.50 (0.25 to 1.50) |
| Day 5 | 0.38 (0.25 to 0.50) | 0.64 (0.25 to 1.03) |
The terminal phase half-life of azacitidine after a single dose (Day 1) or multiple doses (Day 5) for participants with normal renal function and severe renal impairment, calculated according to the following equation: t½ = 0.693/λz, where λz is the terminal phase rate constant.
| hours | Normal RF: Azacitidine 75 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 |
|---|---|---|
| Day 1 | 1.19 ± 102.56 | 0.97 ± 43.88 |
| Day 5 | 1.03 ± 76.95 | 1.15 ± 53.86 |
The apparent total clearance of azacitidine after a single dose (Day 1) and multiple doses (Day 5) for participants with normal renal function and severe renal impairment, calculated as Dose/AUC0-inf.
| liters/hour | Normal RF: Azacitidine 75 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 |
|---|---|---|
| Day 1 | 151.55 ± 30.88 | 85.76 ± 68.83 |
| Day 5 | 166.95 ± 27.59 | 111.55 ± 51.75 |
The apparent volume of distribution of azacitidine after a single dose (Day 1) and multiple doses (Day 5) for participants with normal renal function and severe renal impairment, calculated according to the equation: Vz/F = Apparent total clearance (CL/F) / terminal phase rate constant (λz).
| liters | Normal RF: Azacitidine 75 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 |
|---|---|---|
| Day 1 | 259.44 ± 121.71 | 120.47 ± 120.45 |
| Day 5 | 248.57 ± 115.10 | 184.54 ± 104.34 |
A serious adverse event is one that at any dose of the study drug or at any time during the period of observation: * Results in death; * Is life threatening; * Requires inpatient hospitalization or prolongation of existing hospitalization; * Results in persistent or significant disability/incapacity; * Is a congenital anomaly/birth defect; * Is medically important. The Investigator assessed each AE for potential causal relationship between the event and study drug. The intensity of adverse changes in physical signs or symptoms was graded from 1 to 5 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3, and according to the following: Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3), Life threatening (Grade 4), or Death (Grade 5).
| participants | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 | Extension Phase: Normal RF | Extension Phase: Severe RI |
|---|---|---|---|---|---|---|---|
| Any adverse event | 4 | 3 | 6 | 5 | 6 | 14 | 4 |
| Adverse event related to study drug | 2 | 3 | 4 | 4 | 3 | 8 | 2 |
| Serious adverse event | 0 | 0 | 4 | 1 | 1 | 8 | 3 |
| Serious adverse event related to study drug | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| Grade 3 or 4 adverse event | 0 | 0 | 4 | 1 | 3 | 10 | 3 |
| AE leading to study drug discontinuation | 0 | 0 | 0 | 0 | 0 | 4 | 2 |
| AE leading to study drug interruption | 0 | 0 | 0 | 0 | 0 | 4 | 1 |
| AE leading to a dose reduction | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| AE leading to other action taken | 2 | 1 | 6 | 4 | 5 | 10 | 3 |
| Death | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Collected over Initial treatment phase: Days 1-11 for participants who received a single dose; Days 1-29 for participants who received multiple doses. Extension treatment period: From the date of first dose until 28 days after the date of last dose (up to 7 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Azacitidine 25 mg/m^2 | — | 0/5 (0%) | 4/5 (80%) |
| Azacitidine 50 mg/m^2 | — | 0/5 (0%) | 3/5 (60%) |
| Azacitidine 75 mg/m^2 | — | 4/6 (66.7%) | 5/6 (83.3%) |
| Azacitidine 100 mg/m^2 | — | 1/5 (20%) | 5/5 (100%) |
| Severe RI: Azacitidine 75 mg/m^2 | — | 1/6 (16.7%) | 6/6 (100%) |
| Extension Phase: Normal RF | — | 8/14 (57.1%) | 9/14 (64.3%) |
| Extension Phase: Severe RI | — | 3/4 (75%) | 4/4 (100%) |
| Event | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 | Extension Phase: Normal RF | Extension Phase: Severe RI |
|---|---|---|---|---|---|---|---|
| DyspneaRespiratory, thoracic and mediastinal disorders | 0/5 | 0/5 | 0/6 | 0/5 | 0/6 | 0/14 | 2/4 |
| NauseaGastrointestinal disorders | 0/5 | 0/5 | 2/6 | 0/5 | 0/6 | 1/14 | 0/4 |
| VomitingGastrointestinal disorders | 0/5 | 0/5 | 2/6 | 0/5 | 0/6 | 0/14 | 1/4 |
| Small intestinal obstructionGastrointestinal disorders | 0/5 | 0/5 | 1/6 | 0/5 | 0/6 | 1/14 | 1/4 |
| FatigueGeneral disorders | 0/5 | 0/5 | 0/6 | 0/5 | 0/6 | 0/14 | 1/4 |
| Hemoglobin decreasedInvestigations | 0/5 | 0/5 | 0/6 | 0/5 | 0/6 | 0/14 | 1/4 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/5 | 0/5 | 0/6 | 0/5 | 0/6 | 1/14 | 1/4 |
| HyponatremiaMetabolism and nutrition disorders | 0/5 | 0/5 | 0/6 | 1/5 | 0/6 | 1/14 | 0/4 |
| Back painMusculoskeletal and connective tissue disorders | 0/5 | 0/5 | 0/6 | 1/5 | 0/6 | 0/14 | 0/4 |
| AnemiaBlood and lymphatic system disorders | 0/5 | 0/5 | 1/6 | 0/5 | 0/6 | 0/14 | 0/4 |
| Event | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 | Extension Phase: Normal RF | Extension Phase: Severe RI |
|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 0/5 | 0/5 | 2/6 | 3/5 | 2/6 | 3/14 | 1/4 |
| NeutropeniaBlood and lymphatic system disorders | 0/5 | 0/5 | 0/6 | 0/5 | 2/6 | 2/14 | 2/4 |
| NauseaGastrointestinal disorders | 0/5 | 0/5 | 1/6 | 2/5 | 0/6 | 2/14 | 2/4 |
| VomitingGastrointestinal disorders | 0/5 | 0/5 | 3/6 | 0/5 | 0/6 | 0/14 | 1/4 |
| Injection site painGeneral disorders | 0/5 | 2/5 | 1/6 | 1/5 | 2/6 | 0/14 | 0/4 |
| AnaemiaBlood and lymphatic system disorders | 0/5 | 0/5 | 1/6 | 0/5 | 2/6 | 1/14 | 1/4 |
| Injection site reactionGeneral disorders | 0/5 | 0/5 | 2/6 | 0/5 | 0/6 | 0/14 | 0/4 |
| Decreased appetiteMetabolism and nutrition disorders | 0/5 | 0/5 | 2/6 | 1/5 | 0/6 | 2/14 | 0/4 |
| ConstipationGastrointestinal disorders | 1/5 | 0/5 | 1/6 | 0/5 | 0/6 | 4/14 | 1/4 |
| LeukopeniaBlood and lymphatic system disorders | 0/5 | 0/5 | 0/6 | 0/5 | 0/6 | 2/14 | 1/4 |
Safety population. The total number of participants in the study was 27; 18 continued treatment in the extension phase.
| Age, Continuous(years) | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 | Extension Phase: Normal RF | Extension Phase: Severe RI | Total |
|---|---|---|---|---|---|---|---|---|
| Initial Treatment Period | 67.6 ± 3.78 | 64.6 ± 9.63 | 53.5 ± 10.19 | 57.0 ± 12.02 | 74.5 ± 12.58 | NA ± NA | NA ± NA | 63.5 ± 12.32 |
| Extension Treatment Period | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 60.6 ± 9.52 | 68.8 ± 11.0 | 62.4 ± 10.15 |
| Sex/Gender, Customized(participants) | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 | Extension Phase: Normal RF | Extension Phase: Severe RI | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 3 | 3 | 3 | 4 | 3 | 0 | 0 | 16 |
| Male | 2 | 2 | 3 | 1 | 3 | 0 | 0 | 11 |
| Race/Ethnicity, Customized(participants) | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 | Extension Phase: Normal RF | Extension Phase: Severe RI | Total |
|---|---|---|---|---|---|---|---|---|
| Black | 1 | 2 | 1 | 2 | 2 | 0 | 0 | 8 |
| White | 4 | 3 | 5 | 3 | 4 | 0 | 0 | 19 |
| Region of Enrollment(participants) | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 | Extension Phase: Normal RF | Extension Phase: Severe RI | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 5 | 5 | 6 | 5 | 6 | 0 | 0 | 27 |
| Gender of Extension Period Participants(participants) | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 | Extension Phase: Normal RF | Extension Phase: Severe RI | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 8 | 2 | 10 |
| Male | 0 | 0 | 0 | 0 | 0 | 6 | 2 | 8 |
| Race: Extension Phase(participants) | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 | Extension Phase: Normal RF | Extension Phase: Severe RI | Total |
|---|---|---|---|---|---|---|---|---|
| Black | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 5 |
| White | 0 | 0 | 0 | 0 | 0 | 9 | 4 | 13 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status: Initial Treatment Phase(participants) | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 | Extension Phase: Normal RF | Extension Phase: Severe RI | Total |
|---|---|---|---|---|---|---|---|---|
| 0 | 2 | 2 | 1 | 0 | 2 | 0 | 0 | 7 |
| 1 | 3 | 3 | 4 | 5 | 3 | 0 | 0 | 18 |
| 2 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status: Extension Phase(participants) | Azacitidine 25 mg/m^2 | Azacitidine 50 mg/m^2 | Azacitidine 75 mg/m^2 | Azacitidine 100 mg/m^2 | Severe RI: Azacitidine 75 mg/m^2 | Extension Phase: Normal RF | Extension Phase: Severe RI | Total |
|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 3 |
| 1 | 0 | 0 | 0 | 0 | 0 | 11 | 3 | 14 |
| 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
3 further baseline measures are reported on the registry.
Ran from Nov 2008 to primary completion in Jul 2012, 44 months.
Results were first posted in Oct 2013, 1 year 3 months after primary completion.
Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 44 months is close to that.
Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azacitidine